Market
Which major pharmaceutical company will invest in psilocybin research by end of 2025?
3
Resolution / Starting Odds
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
Roche • 25%
Company press releases and financial reports
Story
Psilocybin Therapy Cuts Depression by Over 70% in COVID Healthcare Workers
Dec 5, 2024, 04:07 PM
A study published by the American Medical Association has found that psilocybin therapy, derived from magic mushrooms, led to a significant and sustained reduction in symptoms of depression among frontline healthcare workers, including doctors and nurses, who served during the COVID-19 pandemic. The therapy reduced depression scores by over 70%, compared to a 30% reduction observed with a placebo. Participants experienced an average drop in depression scores, underscoring the potential of psilocybin as a therapeutic option for mental health challenges faced by healthcare professionals.
View original story
Similar markets
Ayahuasca • 25%
Other • 25%
Psilocybin • 25%
LSD • 25%
Novartis • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Other • 25%
Roche • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Merck • 25%
Pfizer • 25%
Other • 25%
Yes • 50%
No • 50%
Other • 25%
AstraZeneca • 25%
Moderna • 25%
Pfizer • 25%
Roche • 25%
Other • 25%
Novartis • 25%
Pfizer • 25%
Roche • 25%
Sanofi • 25%
Other • 25%
Pfizer • 25%
Other • 25%
Johnson & Johnson • 25%
Moderna • 25%
Pfizer • 25%
Yes • 50%
No • 50%
Roche • 25%
AstraZeneca • 25%
Daiichi Sankyo • 25%
Pfizer • 25%